MaxCyte Sees FY2026 Sales $30.000M-$32.000M vs $38.405M Est

Benzinga Newsdesk www.benzinga.com Positive 80.6%

Neg 0% Neu 0% Pos 80.6%

MaxCyte (NASDAQ:MXCT) sees FY2026 sales of $30.000 million-$32.000 million vs $38.405 million analyst estimate.

Comments

No comments yet. Be the first!